Chromocell therapeutics announces closing of initial public offering for gross proceeds of $6.6 million

Freehold, n.j., feb. 21, 2024 (globe newswire) -- chromocell therapeutics corporation (nyse american: chro) (“chromocell”, “our”, “us” or the “company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share. the gross proceeds from the offering to chromocell, before deducting the underwriting discounts and estimated offering expenses, were approximately $6.6 million. chromocell's common stock is listed on the nyse american llc under the ticker symbol “chro”.
CHRO Ratings Summary
CHRO Quant Ranking